Thema: US79957L1008
SMTI, US79957L1008
stock-5051155_1920.jpg - Foto: THN
Sanara MedTech stock: Q3 revenue rises, outlook is cut
Sanara MedTech stock posted third-quarter revenue growth, but lowered its full-year 2026 sales outlook. Merger costs weighed on earnings.
ad-hoc-news.de, vor 50 Minuten
SMTI, US79957L1008
Sanara MedTech stock: FTC extends merger review. Sanara ...
The October 15, 2026 FTC request added 30 days to the merger wait. Sanara MedTech stock posted USD 28.14 million revenue versus USD 28.95 million expected.
ad-hoc-news.de, 28.10.26 06:41 Uhr
SMTI, US79957L1008
Sanara MedTech stock: FTC extends merger review. Sanara ...
The FTC requested more merger documents on October 15, 2026. Sanara MedTech stock faces a 30-day wait and a year-end 2026 closing target.
ad-hoc-news.de, 24.10.26 03:24 Uhr
SMTI, US79957L1008
FTC second request delays Sanara MedTech merger: 3 analysts ...
Second-quarter revenue reached USD 28.14 million, up 8.93 percent year over year. Sanara MedTech stock has a USD 35.00 target.
ad-hoc-news.de, 21.10.26 03:28 Uhr
SMTI, US79957L1008
Sanara MedTech stock faces an October 15 merger deadline ...
Sanara MedTech stock was last at USD 35 on October 6, 2026, after shareholders approved the MiMedx merger on September 30. HSR review runs to October 15.
ad-hoc-news.de, 07.10.26 03:11 Uhr
SMTI, US79957L1008
Sanara MedTech stock tracks merger approval and October ...
Sanara MedTech stock closed at USD 34.85 on October 2, 2026, 1.4 percent below its 52-week high. Q2 revenue reached USD 28.14 million.
ad-hoc-news.de, 04.10.26 12:35 Uhr
Sanara, Medtech
Sanara Medtech: A Strategic Pivot After a Steep Decline
